{"id":732893,"date":"2023-02-21T07:15:09","date_gmt":"2023-02-21T12:15:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-and-eversana-selected-to-present-results-of-real-world-healthcare-utilization-study-comparing-gimoti-and-oral-metoclopramide-at-the-digestive-disease-week-plenary-session\/"},"modified":"2023-02-21T07:15:09","modified_gmt":"2023-02-21T12:15:09","slug":"evoke-pharma-and-eversana-selected-to-present-results-of-real-world-healthcare-utilization-study-comparing-gimoti-and-oral-metoclopramide-at-the-digestive-disease-week-plenary-session","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-and-eversana-selected-to-present-results-of-real-world-healthcare-utilization-study-comparing-gimoti-and-oral-metoclopramide-at-the-digestive-disease-week-plenary-session\/","title":{"rendered":"Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI\u00ae and Oral Metoclopramide at the Digestive Disease Week Plenary Session"},"content":{"rendered":"

\nDistinguished event features the year\u2019s best abstracts and invited speakers in their fields
\n<\/h2>\n
\n

SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK),<\/a> a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae<\/sup> (metoclopramide) nasal spray, and EVERSANA\u2122,<\/a> a leading provider of global commercial services to the life science industry, today announced that its abstract entitled \u201cReducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide\u201d has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week (DDW) 2023. The meeting will take place May 6-9, 2023 at McCormick Place in Chicago, IL.<\/p>\n

The abstract will be delivered in an oral plenary presentation by David C. Kunkel, MD, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health. Sessions at DDW are the forum for highlighting some of the year\u2019s best research abstracts as determined by the conference organizers. The presentation will highlight data from a retrospective cohort analysis of 514 diabetic gastroparesis patients comparing those receiving either GIMOTI or oral metoclopramide to determine the relative usage of healthcare resources across several settings, such as physician’s offices, emergency rooms, and inpatient and outpatient hospital visits.<\/p>\n

GIMOTI is the first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent DGP. Prior to GIMOTI\u2019s approval by the\u00a0U.S. Food and Drug Administration\u00a0(FDA), oral metoclopramide was the only FDA-approved outpatient treatment for patients suffering from DGP. A nasal route of administration offers systemic absorption in patients with gastroparesis where gastric emptying can be erratic and absorption of oral medications can be unpredictable.<\/p>\n

\u201cThe data to be presented at DDW will speak to the potential of GIMOTI and its effectiveness for gastroparesis patients,\u201d said Dr. Kunkel, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health. \u201cPatients suffering from diabetic gastroparesis run the high risk of visiting the hospital or ER frequently due to a plethora of symptoms associated with the debilitating condition. I am thrilled to share with my colleagues and distinguished members of the DDW community this compelling data based on a novel product that I believe can move the needle in the gastroparesis treatment landscape.\u201d<\/p>\n

\u201cOur core objective when we began this journey well over a decade ago was to provide patients access to a novel product like GIMOTI. We believe GIMOTI can improve gastroparesis treatment by providing a critically needed non-oral drug delivery for gastroparesis. Today, with the clinical and commercial validation we are receiving for GIMOTI, we could not be prouder to share these data at DDW and show that we are indeed attaining our patient-centric goal,\u201d commented Matt D\u2019Onofrio, President and COO of Evoke Pharma.<\/p>\n

\u201cThe value of real-world evidence has never been more important to demonstrate the effectiveness of novel therapies like GIMOTI,\u201d added Jim Lang, CEO at EVERSANA. \u201cThrough our robust data sets and experts at EVERSANA, we\u2019re able to assess the impact of GIMOTI across multiple stakeholders, including doctors, payers and patients across diverse demographic and clinical settings.\u201d<\/p>\n

\n Details of the presentation are as follows: <\/strong>\n <\/p>\n

Distinguished Plenary Presentation Title: \u201cReducing Real-World Healthcare Resource Utilization for Patients with Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide\u201d<\/p>\n

Presentation Date & Time: May 9, 2023, from 8:00 AM to 9:30 AM CDT<\/p>\n

Presenter: Dr. David C. Kunkel, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health<\/p>\n

Location: McCormick Place, Chicago, IL<\/p>\n

\n About\u00a0Evoke Pharma, Inc.<\/strong>
\n
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in\u00a0the United States\u00a0to treat gastroparesis.<\/p>\n

Visit\u00a0www.EvokePharma.com<\/a>\u00a0for more information.<\/p>\n

Follow GIMOTI on Facebook:\u00a0https:\/\/www.facebook.com\/GIMOTI-metoclopramide-nasal-spray-104672345100289<\/a>
Follow\u00a0Evoke Pharma\u00a0on Facebook:\u00a0https:\/\/www.facebook.com\/Evoke-Pharma-Inc-131313647029724<\/a>
Follow\u00a0Evoke Pharma\u00a0on LinkedIn:\u00a0https:\/\/www.linkedin.com\/company\/evoke-pharma\/<\/a><\/p>\n

\n About EVERSANA <\/strong>
\n
EVERSANA\u2122 is the leading independent provider of global services to the life sciences industry. The company\u2019s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit\u00a0eversana.com<\/a>\u00a0or connect through\u00a0LinkedIn<\/a>\u00a0and\u00a0Twitter<\/a>.<\/p>\n

\n About Gimoti<\/strong>\u00ae (metoclopramide) nasal spray<\/strong>
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.<\/p>\n

\n Important Safety Information<\/strong>
\n
WARNING: TARDIVE DYSKINESIA<\/p>\n